- For Comparison Group I: Currently pregnant women (maternal report validated by medical records) diagnosed with hypercholesterolemia and ASCVD, or hypercholesterolemia associated with FH but who were not exposed to evolocumab during pregnancy or any time within 90 days prior to the first day of the LMP.